ObsEva SA: ObsEva Announces Additional Efficacy Results for

ObsEva SA: ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectively

Related Keywords

Geneva , Genè , Switzerland , Japan , Japanese , Swiss , Shauna Dillon , Hugh Taylor , Exchange Commission , Yale University , Endometriosis Health Profile , World Endometriosis Research Foundation , Kissei Pharmaceutical Co Ltd , Swiss Exchange , Program In Endometriosis , Chief Medical Officer , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Obseva , Nnounces , Dditional , Efficacy , Results , Linzagolix , Back , Therapy , Without , Hase , Edelweiss , Trial , Patients , Moderate , Evere , Endometriosis , Ssociated , Rain ,